Fate Therapeutics Chooses CEO—Will Be Based in San Diego

After a months-long hunt, Fate Therapeutics, the superstar-laden, bi-coastal stem cell startup backed chiefly by Waltham, MA-based Polaris Venture Partners and Arch Venture Partners of Seattle, has named its CEO, the Seattle Times reported and company sources confirmed today. The CEO choice is Paul Grayson, previously of the San Diego arm of California-based Sanderling Ventures, which focuses on biomedical startups.

Grayson’s appointment means Fate will be based in San Diego. Fates’s five scientific co-founders are based in the Boston, Seattle, and San Diego areas, so it’s not a big surprise that one of those cities would be chosen as the firm’s headquarters. We recently chronicled the story of Fate’s formation here.

Bob is Xconomy's founder and editor in chief. You can e-mail him at bbuderi@xconomy.com, call him at 617.500.5926. Follow @bbuderi

Trending on Xconomy